

**RENALC'24**

Global Forum on  
Renal Cancer

**BLADDR'24**

Global Forum on  
Bladder Cancer

## PROGRAMME

# Global Forum on Renal and Bladder Cancer

26-28 November 2024  
Vienna Marriott Hotel, Austria

[renalc.org](https://renalc.org) | [bladdr.org](https://bladdr.org)





# Welcome

## Dear colleagues, dear friends,

Congratulations, you've made it to Vienna, the destination of your RENALC and BLADDR journeys! Some say the journey is more important than the destination. We say: they are equally important. The journeys with the patient case challenges were the ideal warm-up for the real workout: RENALC 2024 and BLADDR 2024.

For 2024, our focus remains on identifying the impact that new data and treatments have on best practice, and how to translate these into your daily clinical practice in order to improve patient management.

To achieve this, we will bring together an international multidisciplinary top faculty to present the data along with a panel of experts who will shape these data into recommendations on the spot, in a new discussion-based format where you will also have a voice!

Yes, in these meetings, you will:

- **get a full update on renal cancer and bladder cancer**
- **learn from keynote speakers about the major clinical advances for your practice**
- **get the chance to interact and challenge the expert panel during case discussions**
- **share a coffee and your views with top leaders**

Join the discussions and participate in the lively debates! Ready, set, go!

**Welcome to Vienna!**

Share your photos  
and thoughts on   
**@mirrorsmed**  
**#RENALC24**  
**#BLADDR24**

## Organising committee



**Philippe Barthélémy**  
Medical Oncology  
Strasbourg, France



**Manuela Schmidinger**  
Medical Oncology  
Vienna, Austria



**Bernadett Szabados**  
Urology  
London, UK

## Faculty

**Philippe Barthélémy**  
Medical Oncology  
Strasbourg, France

**Axel Bex**  
Urology  
London, UK

**Saeed Dabestani**  
Urology  
Malmö, Sweden  
[@DrDabestani](#)

**Ignacio Duran**  
Medical Oncology  
Santander, Spain  
[@nachoduranm](#)

**Petros Grivas**  
Medical Oncology  
Seattle, USA  
[@PGrivasMDPhD](#)

**Géraldine Pignot**  
Urology  
Marseille, France  
[@PignotG](#)

**Renate Pichler**  
Urology  
Innsbruck, Austria  
[@Renate\\_Pichler](#)

**Lisa Pickering**  
Medical Oncology  
London, UK  
[@lisapic](#)

**Manuela Schmidinger**  
Medical Oncology  
Vienna, Austria  
[@schmidingerRCC](#)

**Bernadett Szabados**  
Urology  
London, UK  
[@b\\_szabados](#)

## Tuesday 26 November

13:00	<b>Official opening</b> Manuela Schmidinger, Philippe Barthélémy
13:15	<b>Congress highlights with impact on clinical practice</b> Moderator: Axel Bex Localised RCC - Bernadett Szabados Metastatic RCC - Ignacio Duran Discussion and Q&A
13:45	<b>High-risk RCC after nephrectomy and oligometastatic RCC</b> Moderators: Ignacio Duran, Lisa Pickering Risk assessment of post-nephrectomy patients - Philippe Barthélémy Debate: Weighing the pros and cons of adjuvant therapy - Saeed Dabestani, Manuela Schmidinger Cyto-reductive nephrectomy: the history - Saeed Dabestani To operate or not? Debate on deferred cyto-reductive nephrectomy - Axel Bex, Géraldine Pignot Discussion and Q&A
15:15	<b>Break</b>
15:45	<b>Case discussion session: Selecting treatment for metastatic RCC</b> Moderators: Philippe Barthélémy, Bernadett Szabados Panel onsite: Philippe Barthélémy, Ignacio Duran, Renate Pichler, Lisa Pickering, Manuela Schmidinger, Bernadett Szabados Panel not onsite: Amarnath Challapalli, Daan De Maeseneer, Javier Puente Mirrors of Medicine – case-based approach - Petros Grivas Case presentation - Petros Grivas Selecting first-line treatment for advanced clear-cell RCC - Manuela Schmidinger Treatment options for patients with metastatic papillary RCC - Lisa Pickering Panel discussion and Q&A
17:15	<b>Looking ahead: RCC management in 2025</b> Moderator: Saeed Dabestani View of the urologist - Axel Bex View of the medical oncologist - Philippe Barthélémy Discussion and Q&A
18:00	<b>End of RENALC &amp; reception</b>



## TAKE CONTROL OF RCC WITH CABOMETYX® + nivolumab



### TAKE CONTROL OF THE DISEASE

With efficacy demonstrated in pivotal trial across RCC<sup>1-5</sup>



### TAKE CONTROL OF THE TREATMENT EXPERIENCE

With flexible dosing and a predictable, well-understood safety profile<sup>6</sup>



### TAKE CONTROL OF THE PATIENT EXPERIENCE

With manageable side effects and low discontinuation rates<sup>1-6</sup>

\* Cabozantinib is indicated as monotherapy for advanced renal cell carcinoma:<sup>6</sup>

As first-line treatment of adult patients with intermediate or poor risk. In adults following prior vascular endothelial growth factor (VEGF)-targeted therapy. Cabozantinib, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults.<sup>6</sup>

RCC: renal cell carcinoma

1. Choueiri TK et al. Eur J Cancer. 2018;94:115–125. 2. Motzer RJ et al. Br J Cancer. 2018;118(9):1176–1178. 3. Powles T, et al. J Clin Oncol 2022; 40(suppl 6): 350. 4. Abou-Alfa GK et al. N Engl J Med. 2018;379(1):54–63. 5. Brose, Marcia S., et al. The Lancet Oncol. 22.8 (2021):1126-1138.

6. CABOMETYX® Professional Information

CBZ-AT-002502 09/2024



PRODUCT  
INFORMATION



# RENALC thanks its sponsors and partners

## Principal sponsor




## Silver sponsor



## Bronze sponsors



## Partners



## Global organising committee



**Ananya Choudhury**  
Clinical Oncology  
Manchester, UK



**Maria De Santis**  
Uro-Oncology  
Berlin, Germany



**Badrinath Konety**  
Urology  
Minneapolis, USA

## Local organising committee



**Eva Compérat**  
Pathology  
Vienna, Austria



**Kilian Gust**  
Urology  
Vienna, Austria



**Dora Niedersüß-Beke**  
Medical Oncology  
Vienna, Austria

## Faculty

**Vérane Achard**  
Radiation Oncology  
Fribourg, Switzerland  
[@Achard\\_Verane](#)

**Dirk Beyersdorff**  
Radiology  
Hamburg, Germany

**Ananya Choudhury**  
Clinical Oncology  
Manchester, UK  
[@achoud72](#)

**Eva Compérat**  
Pathology  
Vienna, Austria  
[@evacomperat](#)

**Marco de Felice**  
Patient representative  
Vienna, Austria

**Daan De Maeseneer**  
Medical Oncology  
Bruges & Ghent, Belgium  
[@daandm](#)

**Ben-Max de Ruiter**  
Urology  
Alkmaar & Amsterdam,  
the Netherlands

**Maria De Santis**  
Medical Oncology  
Berlin, Germany  
[@mdesantis234](#)

**Ignacio Durán**  
Medical Oncology  
Santander, Spain  
[@nachoduranm](#)

**Petros Grivas**  
Medical Oncology  
Seattle, USA  
[@PGrivasMDPhD](#)

**Kilian Gust**  
Urology  
Vienna, Austria  
[@KilianGust](#)

**Peter Hoskin**  
Clinical Oncology  
Northwood & Manchester &  
London, UK

**Rob Jones**  
Medical Oncology  
Glasgow, UK

**Badrinath Konety**  
Urology  
Minneapolis, US  
[@bkonety](#)

**Suma Konety**  
Cardio-oncology  
Minneapolis, US

**Cédric Lebâcle**  
Urology  
Paris, France  
[@CLEbacle](#)

**Laura Mertens**  
Urology  
Amsterdam, The Netherlands  
[@LAUrology\\_NL](#)

**Dora Niedersüß-Beke**  
Medical Oncology  
Vienna, Austria

**Renate Pichler**  
Urology  
Innsbruck, Austria  
[@Renate\\_Pichler](#)

**Géraldine Pignot**  
Urology  
Marseille, France  
[@PignotG](#)

**Daniele Raggi**  
Medical Oncology  
London, UK  
[@DanieleRaggi83](#)

**Celena Scheede-Bergdahl (virtual)**  
Physiotherapy  
Montreal, Canada  
[@CelenaBergdahl](#)

**Bernadett Szabados**  
Urology  
London, UK  
[@b\\_szabados](#)

**Gunhild von Amsberg**  
Medical Oncology  
Hamburg, Germany


**Fred Witjes**  
Urology  
Nijmegen, the Netherlands

# Wednesday 27 November

09:00	<b>Official opening</b> Eva Compérat, Kilian Gust
09:15	<b>Staging, monitoring and response prediction: utility or futility of novel approaches</b> Moderators: Ananya Choudhury, Fred Witjes <ul style="list-style-type: none"> <li>Role of AI for diagnosis and monitoring bladder cancer - Eva Compérat</li> <li>How can mpMRI change management of patients with NMIBC or MIBC? - Dirk Beyersdorff</li> <li>Can AI drive treatment decision-making in NMIBC? - Badrinath Konety</li> </ul> Discussion and Q&A
10:10	<b>MIBC congress highlights from ESMO</b> Moderator: Renate Pichler Presenter: Maria De Santis
10:40	<b>Debate: the role of ctDNA to manage MIBC in the adjuvant setting</b> Moderator: Daniele Raggi Presenters: Petros Grivas, Bernadett Szabados
11:05	<b>Break</b>
11:30	<b>Case discussion session: NMIBC</b> Moderators: Maria De Santis, Renate Pichler Panel: Ben-Max de Ruiter, Maria De Santis, Petros Grivas, Kilian Gust, Badrinath Konety, Cédric Lebâcle, Laura Mertens, Renate Pichler, Géraldine Pignot, Fred Witjes <ul style="list-style-type: none"> <li>Mirrors of Medicine – case-based approach - Petros Grivas</li> <li>Case presentation - Daan De Maeseneer</li> <li>Debate: Are we ready to de-intensify treatment and surveillance in low-grade NMIBC? - Kilian Gust, Cédric Lebâcle</li> <li>High-risk BCG-naïve NMIBC: should we stick to BCG? - Ben-Max de Ruiter</li> <li>High-risk BCG-unresponsive NMIBC: are we ready to delay/avoid RC? - Petros Grivas</li> </ul> Panel discussion and Q&A
13:00	<b>Lunch</b>
14:00	<b>RC and neobladder</b> Moderators: Dora Niedersüß-Beke, Badrinath Konety <ul style="list-style-type: none"> <li>Prehabilitation programme - Celena Scheede-Bergdahl (virtual)</li> <li>Patient selection for neobladder - Laura Mertens</li> <li>Patient testimony on living with a neobladder - Marco de Felice</li> </ul> Panel discussion and Q&A

# Wednesday 27 November

15:00	<b>First-line treatment for advanced UCa: balancing between efficacy, safety, patient characteristics and QoL</b> Moderator: Dora Niedersüß-Beke Presenter: Gunhild von Amsberg
15:30	<b>Update lecture: Immunotherapy and cardiac complications</b> Moderator: Gunhild von Amsberg Presenter: Suma Konety
16:00	<b>Break</b>
16:30	<b>Case discussion session: MIBC</b> Moderators: Ben-Max de Ruiter, Dirk Beyersdorff Panel: Ananya Choudhury, Ben-Max de Ruiter, Ignacio Duran, Peter Hoskin, Rob Jones, Badrinath Konety, Cédric Lebâcle, Daniele Raggi, Gunhild von Amsberg, Fred Witjes <ul style="list-style-type: none"> <li>Case presentation - Daan De Maeseneer</li> <li>Personalised TMT - Peter Hoskin</li> <li>New combinations and concepts of (neo)adjuvant therapy to RC or TMT for MIBC - Ignacio Duran</li> <li>Debate: Withholding radical treatment after CR with neoadjuvant treatment: future-talk or not? - Petros Grivas, Fred Witjes</li> </ul> Panel discussion and Q&A
18:00	<b>End of day 1 &amp; reception</b>



# Thursday 28 November

08:55	<b>Opening day 2</b>
09:00	<b>Practical surgical questions</b> Moderator: Cédric Lebâcle  Practical aspects of intravesical instillation - Fred Witjes The optimal TURBT - Ben-Max de Ruiter The impact of RC on sexual function/experience - Géraldine Pignot Q&A
09:45	<b>Looking ahead: BCa management in 2025</b> Moderator: Badrinath Konety  View of the urologist - Kilian Gust View of the radiation oncologist - Vérane Achard View of the medical oncologist - Rob Jones Discussion and Q&A
10:30	<b>Multidisciplinary discussion on molecular testing</b> Moderator: Bernadett Szabados Panel: Eva Compérat, Maria De Santis
11:00	<b>Break</b>
11:30	<b>Case discussion session: metastatic UCa</b> Moderators: Peter Hoskin, Bernadett Szabados Panel: Ananya Choudhury, Maria De Santis, Ignacio Duran, Petros Grivas, Dora Niedersüß-Beke, Peter Hoskin, Rob Jones, Daniele Raggi, Bernadett Szabados  Case presentation - Daan De Maeseneer Are ADCs a better partner for IO than platinum-based chemotherapy? - Daniele Raggi Do real-world data confirm trial data of the new SOC in first line? - Dora Niedersüß-Beke Treatment sequencing in the era of combination therapies - Rob Jones Histological subtypes in the metastatic setting: what now? - Ananya Choudhury Panel discussion and Q&A
13:00	<b>End of BLADDR</b>

## BLADDR thanks its sponsors and partners

### Principal sponsor



### Silver sponsors



### Bronze sponsors




### Exhibition sponsor



### Educational sponsors



### Partners





In locally advanced or metastatic urothelial carcinoma

# STRATEGIZE FOR QUALITY SURVIVAL WITH BAVENCIO 1L MAINTENANCE<sup>1,2</sup>

**BAVENCIO**<sup>®</sup>  
avelumab 20 mg/mL  
Concentrate for solution for infusion

Extended  
survival

**JB100 primary endpoint:**  
**mOS from start of BAVENCIO**  
**1L maintenance 23.8 months**  
vs 15.0 months (2-sided  $p < 0.0036$ )<sup>1,\*</sup>

More  
quality  
time

**JB100 Q-TWiST analysis:**  
Twice as much **time without toxicity**  
**or symptoms** of disease progression  
(mean 11.98 vs 5.52 months)<sup>2,†</sup>



Actor portrayal,  
not real patient

**MERCK**

\*Data cutoff: June 4, 2021; median follow-up:  $\geq 38$  months. OS measured from time of randomization to BAVENCIO 1LM + BSC or BSC alone in patients who were progression-free after 4 to 6 cycles of 1L platinum-based CT. [mOS 23.8 months (95% CI: 19.9, 28.8) versus 15.0 months (95% CI: 13.5, 18.2); Stratified HR 0.76 (95% CI: 0.63, 0.91)]. <sup>†</sup>Post-hoc analysis; median follow-up of  $\geq 38$  months. Q-TWiST analysis is an integrated measure that incorporates efficacy (OS, PFS), safety (toxicity), and utility estimates (overall health status) into a single value to demonstrate quality and quantity of observed survival time. [11.98 (95% CI: 10.722, 13.202) versus 5.52 (95% CI: 4.516, 6.530)]. **1L**=first-line; **1LM**=1L maintenance; **BSC**=best supportive care; **CI**=confidence interval; **CT**=chemotherapy; **HR**=hazard ratio; **JB100**=JAVELIN Bladder 100; **mOS**=median overall survival; **OS**=overall survival; **PFS**=progression-free survival; **Q-TWiST**=quality-adjusted time without cancer symptoms or toxicity.

**1.** Powles T, et al. *J Clin Oncol*. 2023;41(19):3486-3492. **2.** Powles T, et al. Abstract No. 4515. Presented at the 2023 ASCO Annual Meeting, June 2–6, 2023; Chicago, IL, USA.

©2024 Merck KGaA, Darmstadt, Germany or its affiliates. All rights reserved. BAVENCIO is a registered trademark of Merck KGaA, Darmstadt, Germany or its affiliates. GL-AVE-00670 11/24



Please refer to the EMA product label for the full current prescribing information.

Scan the QR code.



## Practical information

### Onsite contacts

<b>General information</b>	Hanne Kraat	+32 479 10 85 98
<b>Exhibitors &amp; sponsors</b>	Luc Van Ruysevelt	+32 476 25 82 94

### Opening hours registration & information desk

Tuesday 26 November:	10:00 - 18:00
Wednesday 27 November:	08:00 - 18:00
Thursday 28 November:	08:00 - 14:00

## Accreditation points



**RENALC 2024 - Global Forum on Renal cell Cancer (1<sup>st</sup> edition), Vienna & hybrid, Austria 26/11/2024**, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with **4.0** European CME credits

(ECMEC®).

**BLADDR 2024 - Global Forum on Bladder Cancer (9th edition), Vienna & hybrid, Austria 27/11/2024-28/11/2024**, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with **10.0** European CME credits (ECMEC®).

Accreditation Statement: Each medical specialist should claim only those credits that he/she actually spent in the educational activity. Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credits to AMA credits can be found at <https://edhub.ama-assn.org/pages/applications>. Live educational activities occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC® credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

## Certificate of attendance

- 1 Go to <https://library.mirrorsmed.org> and log in using your personal credentials you received by email.
- 2 Go to the section **"My certificates"** and **download** your certificate of attendance.

## Certificate of accreditation

- 1 Go to <https://library.mirrorsmed.org> and log in using your personal credentials you received by email.
- 2 Go to the section **"My certificates"** and complete the **evaluation form**.
- 3 After completion, you can **download** your certificate of accreditation.
- 4 Deadline to complete the evaluation form and download the certificate of accreditation: **31 May 2025**.



Go to <https://library.mirrorsmed.org>

  
**Spread  
the word**  
**@mirrorsmed**  
**#RENALC24**  
**#BLADDR24**





- ✓ Prostate cancer
- ✓ Bladder cancer
- ✓ Renal cell carcinoma
- ✓ Breast cancer

- ✔ Weekly case challenges
- ✔ Easy & fast to consume
- ✔ Compare with peers and experts
- ✔ Individual pathways with QuickScan
- ✔ Accredited course per topic



**ppcp.mirrorsmed.org**

## Notes

# Notes

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

# Notes

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....



# Notes

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

# Notes

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....


**RENALC  
2024**

**BLADDR  
2024**

# ALL SESSIONS ARE INTERACTIVE

**JOIN AT  
SLIDO.COM**

**#RENALC or SCAN**



**#BLADDR or SCAN**



## ASK QUESTIONS & ANSWER POLLS VIA YOUR SMARTPHONE

Ask the faculty all your questions and participate in interactive voting via your smartphone.

**WE LOOK FORWARD TO HEARING YOUR OPINION!**